The European Training Network (ETN) Synaptic Dysfunction in Alzheimer Disease (SyDAD) is a research school sponsored by Horizon 2020 Marie Sklodowska Curie Actions that supports 15 Early Stage Researchers (ESRs).
SyDAD is an interdisciplinary PhD programme including an innovative research programme with cutting edge methodology, an excellent training programme, international exchanges and a translational and collaborative orientation.
The aims of SyDAD are:
1. To train 15 Early Stage Researchers to a new generation of researchers with an innovative mind-set and full understanding of the requirements of academia, pharmaceutical companies, the clinics and the societal challenges.
2. To, through a collaborative research programme, elucidate how the different pathways underlying synaptic dysfunction in Alzheimer Disease relate to each other and to identify novel pharmaceutical targets and to elaborate a drug discovery platform for future implementation of the results.
SyDAD consists of four academic organisations and two pharmaceutical companies that all will employ PhD students:
University of Bordeaux
University of Milano
Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)
In addition, collaborations, secondments and training will also take place at:
- Gothenburg University (Contact: Kina.Hoglund@neuro.gu.se)
- AlzeCure Discovery (Contact: firstname.lastname@example.org)
- Serendipity Professionals (Contact: email@example.com)
- Alzheimer Europe (Contact: firstname.lastname@example.org)
- Universitätsklinikum Bonn (Contact:email@example.com)
- University of Veterinary Medicine and Pharmacy, Košice
- KU Leuven (Contact: firstname.lastname@example.org)